ELECTROPHYSIOLOGY FRONTIERS
Innovative catheter ablation system enhancing efficiency and effectiveness in AFib treatment with durable lesion delivery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 783033 % | 335 % | 12 % | (50 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (4286433 %) | (754 %) | (183 %) | (291 %) | (11532 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
ElectroPhysiology Frontiers (EPF) is a MedTech company specializing in the development of advanced catheter ablation systems designed to treat atrial fibrillation (AFib). The company's flagship product aims to simplify and optimize catheter ablation procedures, ensuring quick, effective, and reproducible lesion delivery. EPF's catheter is engineered to provide stability and versatility in both energy delivery and mapping, addressing the critical need for durable and permanent ablation lesions to reduce AFib recurrence rates.
EPF primarily serves healthcare professionals and institutions involved in the treatment of AFib, operating within the global medical technology market. The company's business model revolves around the sale of its innovative catheter systems to hospitals and clinics, generating revenue through product sales and potentially through service agreements for training and support.
EPF's mission is to make pulmonary vein isolation (PVI) safe, easy, efficient, and effective, while its vision focuses on advancing the treatment of atrial fibrillation to positively impact patients, healthcare professionals, and healthcare systems worldwide.
Keywords: catheter ablation, AFib treatment, MedTech, durable lesions, PVI, healthcare innovation, medical devices, electrophysiology, AFib recurrence, global healthcare.